Tolvaptan: Indications and Common Side Effects
Tolvaptan is primarily indicated for slowing disease progression in adults with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression, and for treating euvolemic and hypervolemic hyponatremia in conditions such as SIADH, heart failure, and cirrhosis. 1, 2
Primary Indications
ADPKD (Disease-Modifying Therapy)
The most robust evidence supports tolvaptan use in ADPKD patients at risk of rapid kidney disease progression. Tolvaptan slows eGFR decline by 1.3 ml/min per 1.73 m² per year and reduces total kidney volume growth by 2.7% compared to untreated patients. 1 Additionally, it significantly reduces UTIs, kidney stones, hematuria, and kidney pain events 1.
- Initiation criteria: Adults with ADPKD at risk of rapid progression
- Starting dose: 45 mg upon waking + 15 mg 8 hours later
- Target dose: 90 mg AM + 30 mg PM (titrated over ≥1 week intervals)
- Duration: Continue until approaching kidney replacement therapy 1
Hyponatremia
Tolvaptan is approved for euvolemic and hypervolemic hyponatremia associated with:
- SIADH
- Heart failure
- Cirrhosis
Contraindicated in hypovolemic hyponatremia 2, 3
Common Side Effects
Most Frequent Adverse Effects (>5% incidence)
The most common side effects are directly related to tolvaptan's aquaretic mechanism 2:
- Thirst (most common)
- Dry mouth
- Polyuria and pollakiuria (making large amounts of urine and urinating often)
- Weakness/asthenia
- Constipation
- Increased blood sugar levels
These aquaretic effects occur because tolvaptan blocks vasopressin V2 receptors, causing free water excretion without electrolyte loss 3.
Serious Adverse Effects Requiring Monitoring
Hepatotoxicity (Critical Safety Concern)
Approximately 5% of ADPKD patients treated with tolvaptan develop transaminase elevations >3× upper limit of normal (compared to 1% on placebo). 1 This idiosyncratic drug-induced liver injury typically occurs within the first 18 months and resolves within 1-4 months after discontinuation 1.
Mandatory monitoring protocol:
- Monthly liver function tests for first 18 months
- Every 3 months thereafter until discontinuation
- Morning blood samples before tolvaptan dose 1
Hold tolvaptan if:
- AST/ALT ≥3× ULN or >2× baseline
- AST/ALT >2× ULN with symptoms of liver injury (fatigue, nausea, vomiting, right upper quadrant pain, jaundice) 1
Dehydration and Volume Depletion
Tolvaptan causes significant aquaresis requiring adequate fluid replacement 1, 2. Patients must:
- Drink enough water to replace urinary losses
- Skip doses during volume depletion risk (vomiting, diarrhea, limited water access, warm weather activities)
- Implement a "sick-day plan" 1
Other Notable Adverse Effects
- Small, reversible eGFR reduction (reflects impact on compensatory hyperfiltration) 1
- Hypernatremia risk (>145 mEq/L) with overly rapid correction 4
- Hyperkalemia potential (monitor in patients with K+ >5 mEq/L) 2
Critical Drug Interactions
Contraindicated with strong CYP3A inhibitors (increase tolvaptan levels >80%) 1, 2:
- Antifungals: ketoconazole, itraconazole
- Antibiotics: clarithromycin
- Protease inhibitors: ritonavir, indinavir, saquinavir
Avoid moderate CYP3A inhibitors (increase levels 50-80%): fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice 1, 2
Important Clinical Pitfalls
- Do not use in patients unable to sense thirst - critical safety issue 2
- Contraindicated with anuria - tolvaptan requires urine production to work 2
- Avoid hypertonic saline co-administration 2
- Not for use in children/adolescents - no safety data available 5
- Counsel patients on low-sodium, low-osmolar fluid intake (reduces polyuria burden) 1
The benefit-risk profile of tolvaptan requires careful patient selection, particularly in ADPKD where lifelong treatment is anticipated. The aquaretic side effects significantly impact quality of life, and hepatotoxicity risk necessitates intensive monitoring, especially during the first 18 months 1, 6.